Moderna CEO Bancel served investors lemonade before the market opened on Monday at the interim phase 1 SARS-CoV-2 vaccine data conference. As of Tuesday’s market close the stock has nearly filled in Monday’s gap up. Bancel’s vague responses to very appropriate questions from analysts about antibody levels measured in the 1st 4 volunteers (of 45) vaccinated with mRNA-1273 (messenger RNA encoding the virus’s spike protein) strengthens my suspicion that this COVID-19 vaccine could be a lemon.
In the current era ushered in by cancer vaccine developers, computer modeling can predict precisely which small peptides (chains